A case of propylthiouracil-induced lupus erythematosus accompanied by antineutrophil cytoplasmic antibody-positive vasculitis

Korean Journal of Dermatology

Volumn 43, Issue 4, 2005, Pages 496-500

  Kim, Jae Wang ^a   Kim, Jin Seok ^a  

^a Jeju National University School of Medicine   (South Korea)

Author keywords

Antineutrophil cytoplasmic antibody; Lupus erythematosus; Propylthiouracil; Vasculitis

Indexed keywords

ALLOPURINOL; ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CARBIMAZOLE; CREATININE; CYCLOPHOSPHAMIDE; HISTONE ANTIBODY; HYDRALAZINE; MINOCYCLINE; MYELOPEROXIDASE; NITROGEN; PENICILLAMINE; PHENYTOIN; PREDNISOLONE; PROCAINAMIDE; PROPYLTHIOURACIL; PROTEINASE; QUINIDINE; SALAZOSULFAPYRIDINE; STREPTOLYSIN; THIAMAZOLE; THYROTROPIN;

ADULT; ALLERGIC VASCULITIS; ANCA ASSOCIATED VASCULITIS; ARTICLE; CASE REPORT; COMORBIDITY; DRUG INDUCED DISEASE; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HYPERTHYROIDISM; LUPUS ERYTHEMATOSUS; PLASMAPHERESIS;

EID: 20544447060     PISSN: 04944739     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Mathieu E, Fain O, Sitbon M, Thomas M. Systemic adverse effect of antithyroid drugs. Clin Rheumatol 1999;18:66-68
2. Khurshid I, Sher J. Disseminated intravascular coagulation and vasculitis during propylthiouracil therapy. Postgrad Med J 2000;76:185-186
3. Otsuka S, Kinebuchi A, Tabata H, Yamakagc A, Yamazaki S. Myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis following propylthiouracil therapy. Br J Dermatol 2000;142:828-830
4. Wolf D, Ben-Yehuda A, Okon E, Naparstek Y. Nodular vasculitis associated with propylthiouracil therapy. Cutis 1992;49:253-255
5. Chastain MA, Russo GG, Boh EE, Chastain JB, Falabella A, Millikan LE. Propylthiouracil hypersensitivity: report of two patients with vasculitis and review of the literature. J Am Acad Dermatol 1999;41:757-764
6. Casis FC, Perez JB. Leukocytoclastic vasculitis: a rare manifestation of propylthiouracil allergy. Endocr Pract 2000;6:329-332
7. Herlin T, Birkebaek NH, Wolthers OD, Heegaard NH, Wiik A. Anti-neutrophil cytoplasmic autoantibody (AN CA) profiles in propylthiouracil-induced lupus-like manifestations in monozygotic triplets with hyperthyroidism. Scand J Rheumatol 2002;31:46-49
8. Yamada A, Sato K, Hara M, Tochimoto A, Takagi S, Hizuka N, et al. Propylthiouracil-induced lupus-like syndrome developing in a Graves' patient with a sibling with systemic lupus erythematosus. Intern Med 2002;41: 1204-1208
9. Skaer TL. Medication-induced systemic lupus erythematosus. Clin Ther 1992;14:496-506
10. Prasad GV, Bastacky S. Johnson JP. Propylthiouracil-induced diffuse proliferative lupus nephritis: review of immunological complications. J Am Soc Nephrol 1997;8: 1205-1210
11. Sato-Matsumura KC, Koizumi H, Matsumura T, Takahashi T, Adachi K, Ohkawara A. Lupus erythematosus-like syndrome induced by thiamazole and propylthiouracil. J Dermatol 1994;21:501-507
12. Lee JC, Yoo B, Lim YJ, Kim SH, Lim MK, Cho YS, et al. A case of propylthiouracil-induced lupus. J Kor Rheum Assoc 1999;8:75-78
13. Fritzler MJ. Drugs recently associated with lupus syndromes. Lupus 1994;3:455-459
14. Shen GQ, Shoenfeld Y, Peter JB. Anti-DNA, anti-histone, and anti-nucleosome antibodies in systemic lupus erythematosus and drug-induced lupus. Clin Rev Allergy Immunol 1998;16:321-334
15. Burlingame RW. The clinical utility of antihistone antibodies. Autoantibodies reactive with chromatin in systemic lupus erythematosus and drug-induced lupus. Clin Lab Med 1997;17:367-378
16. Holder SM, Joy MS, Falk RJ. Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother 2002;36:130-147
17. Huang CN, Hsu TC, Chou HH, Tsay GJ. Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan. J Formos Med Assoc 2004; 103:274-279
18. Fujieda M, Hattori M, Kurayama H, Koitabashi Y. Clinical features and outcomes in children with antineutrophil cytoplasmic autoantibody-positive glomerulonephritis associated with propylthiouracil treatment. J Am Soc Nephrol 2003;13:437-445
19. Fiorentino DF. Cutaneous vasculitis. J Am Acad Dermatol 2003;48:311-340
20. Wiik A. Rational use of ANCA in the diagnosis of vasculitis. Rheumatol 2002;41:481-483
21. Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheumatol 2000; 43:405-413
22. Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, Hoshi M, et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 2000;85:4270-4273
23. Morita S, Ueda Y, Eguchi K. Anti-thyroid drug-induced ANCA-associated vasculitis: a case report and review of the literature. Endocr J 2000;47:467-470
24. Freire BA, Paula ID, Paula F, Kallenberg CG, Limburg PC, Queluz TT. Absence of cross-reactivity to myeloperoxidase of anti-thyroid microsomal antibodies in patients with autoimmune diseases. Am J Med Sci 2001; 321:109-112
25. Jiang X, Khursigara G, Rubin RL. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 1994;266:810-813
26. Dhillon SS, Singh D, Doe N, Qadri AM, Ricciardi S, Schwarz MI. Diffuse alveolar hemorrhage and pulmonary capillaritis due to propylthiouracil. Chest 1999;116:1485-1488